Siemens Healthineers Molecular Imaging has entered into a research collaboration with leading healthcare institution Massachusetts General Hospital (MGH) to support the use of theranostics. The ability to diagnose disease with one radiopharmaceutical and treat it with a similar therapeutic agent, theranostics has been used to treat certain types of cancer, including thyroid cancer, prostate cancer, and neuroendocrine cancer. Typically, molecular imaging is used in theranostics to identify the extent of disease and monitor treatment response.
Siemens Healthineers and MGH will establish a Therapy Command Center to support the use of theranostics across MGH and its affiliated centers in Massachusetts, Maine, and New Hampshire. The Therapy Command Center will help MGH collect theranostics-related data, provide real-time monitoring capabilities, and support physicians in determining the most appropriate path forward for each patient.
鈥淭his research collaboration, which is based on a relationship between Siemen Healthineers and Massachusetts General Hospital that spans more than 20 years, will enable innovations along the patient鈥檚 clinical pathway, provide precision diagnoses, and deliver highly effective forms of customized therapy,鈥 said James Williams, PhD, head of Siemens Healthineers Molecular Imaging.
鈥淭he Therapy Command Center helps provide a framework that will enable the integration of a wide variety of patient imaging and laboratory data, combined with population-based data for enhanced individual patient outcomes,鈥 said Umar Mahmood, MD, PhD, chief of nuclear medicine and molecular imaging, Massachusetts General Hospital. 鈥淭his collaboration will help expand theranostics across the region, advancing personalized medicine through precision diagnoses and tailored therapies. Our focus on examining radiation鈥檚 impact on tumors and normal tissues will further improve treatment protocols and outcomes while decreasing toxicity to normal organs.鈥
As part of this collaboration, Siemens Healthineers and MGH researchers will use Biograph Vision Quadra and Biograph Trinion positron emission tomography/computed tomography (PET/CT) scanners to examine the effects of radiation on molecular and biological processes, as well as the toxicity levels in the cancer cells and healthy tissues of patients who receive radiopharmaceutical therapy. Understanding these effects is crucial to advancing the concept of personalized medicine.
For further information on theranostics and Siemens Healthineers, please visit 听
Contact for journalists
Jeff Bell
Phone: +484-868-8346
E-mail: jeffrey.t.bell@siemens-healthineers.com
Siemens Healthineers听pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around 鈧22.4 billion. Further information is available at .
